# **Appendix 7.5 Manipulation under anaesthesia**

Study: Amir-us-Saqlain 200784
Outcome: Pain
Not reported
Study: Amir-us-Saqlain 2007 <sup>84</sup>
Outcome: Function and disability
Not reported

Study: Amir-us-Saqlain 200784					
Outcome: Range of movement –	active abduction (	°)			
Intervention	Time point	No. randomised	Mean	SD	
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	Baseline	23 (16)ª	33.75	11.03	
MUA + steroid injection + PT		20 (17) <sup>a</sup>	29.71	13.05	
Intervention	Time point	No. analysed	Mean	SD	p-value <sup>b</sup>
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	12 weeks	16	151.81	13.19	0.00
MUA + steroid injection + PT		17	122.82	21.08	
Outcome: Range of movement –	active external rot	ation (°)			
Intervention	Time point	No. randomised	Mean	SD	
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	Baseline	23 (16)ª	28.56	24.45	
MUA + steroid injection + PT		20 (17) <sup>a</sup>	33.53	22.96	
Intervention	Time point	No. analysed	Mean	SD	p-value <sup>b</sup>
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	12 weeks	16	83.38	6.61	0.213
MUA + steroid injection + PT		17	76.76	19.76	
Outcome: Range of movement –	active internal rota	ation <sup>c</sup>			
Intervention	Time point	No. randomised	Mean	SD	
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	Baseline	23 (16) <sup>a</sup>	1.00	0.00	
MUA + steroid injection + PT		20 (17) <sup>a</sup>	1.12	0.33	
Intervention	Time point	No. analysed	Mean	SD	p-value <sup>b</sup>
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	12 weeks	16	3.56	0.51	0.00
MUA + steroid injection + PT		17	2.65	0.7	
Outcome: Range of movement –	passive abduction	<i>(°)</i>			
Intervention	Time point	No. randomised	Mean	SD	
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	Baseline	23 (16) <sup>a</sup>	45.88	14.91	
MUA + steroid injection + PT		20 (17)ª	40.18	17.01	

<sup>©</sup> Queen's Printer and Controller of HMSO 2012. This work was produced by Maund et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

Intervention	Time point	No. analysed	Mean	SD	p-value <sup>b</sup>
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	12 weeks	16	160.25	12.1	0.00
MUA + steroid injection + PT		17	137.76	15.21	
Outcome: Range of movement -	passive external ro	otation (°)			
Intervention	Time point	No. randomised	Mean	SD	
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	Baseline	23 (16)ª	37	23.22	
MUA + steroid injection + PT		20 (17) <sup>a</sup>	41.47	23.77	
Intervention	Time point	No. analysed	Mean	SD	p-value <sup>b</sup>
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	12 weeks	16	91.25	6.45	0.200
MUA + steroid injection + PT		17	86.41	13.38	
Outcome: Range of movement –	passive internal ro	tation <sup>c</sup>			
Intervention	Time point	No. randomised	Mean	SD	
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	Baseline	23 (16)ª	1	0.00	
MUA + steroid injection + PT		20 (17) <sup>a</sup>	1.18	0.39	
Intervention	Time point	No. analysed	Mean	SD	p-value <sup>b</sup>
MUA + steroid injection + manipulated extremity kept in abduction and external rotation + PT	12 weeks	16	3.88	0.34	0.00
MUA + steroid injection + PT		17	2.88	0.49	

#### PT, physiotherapy.

c Internal rotation was measured by spinal level (the metric used was not explicitly stated in the paper, but appears to be cm).

Note: Other range of movements reported, which were not of relevance to this review and are therefore not presented in the data extraction tables, included active forward flexion and passive forward flexion.

# Study: Amir-us-Saqlain 200784

Outcome: Quality of life

a Baseline data not reported for patients lost to follow-up.

b *p*-value for between-group difference.

#### Study: Amir-us-Saqlain 200784

Outcome: Other

Not reported

## Study: Amir-us-Saqlain 200784

Outcome: Adverse events

Not reported

## Study: Jacobs 200985

olaaj. oaceze zeee					
Outcome: Pain measur	red using 100-point VA	S			
Intervention	Time point	No. randomised	Mean	SD	
MUA Steroid + distension	Baseline	28 25	Baseline data not re	ported	
Intervention	Time point	No. analysed	Mean regression coefficient	SE	p-value, 95% Cl
MUA Steroid + distension	16 weeks	19 24	-2.77 -2.75	0.33 0.42	Not significant, <sup>b</sup> –1.11 to 1.15

- a Data presented graphically; only mean regression coefficients reported.
- b Exact *p*-value not reported.

Study: Jacobs 200985						
Outcome: Function an	nd disability measured by	y the Constant scoreª				
Intervention	Time point	No. randomised	Mean	SD		
MUA	Baseline	28	Baseline data not re	ported		
Steroid + distension		25				
Intervention	Time point	No. analysed	Mean regression coefficient	SE	p-value,⁵ 95% Cl	
MUA	16 weeks	19	3.13	0.24	Not significant,	
Steroid + distension		24	3.23	0.42	-0.90 to 1.11	

- a Data presented graphically.
- b p-value is for between-group difference; only mean regression coefficients reported.

Study: Jacobs 200985

Outcome: Range of movement

<sup>©</sup> Queen's Printer and Controller of HMSO 2012. This work was produced by Maund et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

## Study: Jacobs 200985

Outcome: Quality of life, SF-36 components (general health, bodily pain, physical role, emotional role, social functioning, bodily pain, vitality, mental health)<sup>a</sup>

• ,					
Intervention	Time point	No. randomised	Mean	SD	
MUA Steroid + distension	Baseline	28 25	Baseline data not repor	ted	
Intervention	Time point	No. analysed	Results reported		p-value <sup>b</sup>
MUA Steroid + distension	24 months	19 24	All components of the S patients during the cou physical role and bodily the greatest improvement	rse of treatment. The pain components showed	Not significant

- a Data reported graphically and brief description in text only.
- b *p*-value is for between-group difference.

Study: Jacobs 200985

Outcome: Other

Not reported

Study: Jacobs 200985

Outcome: Adverse events

Study: Kivimaki 2007 <sup>39</sup>				
Outcome: Pain (pain intensity) ı	neasured using Likert	0–10 scale		
Intervention <sup>a</sup>	Time point	No. randomised	Mean	SD
MUA + PT	Baseline	65	6.6	0.3
Home exercise		60	6.4	0.3
Intervention <sup>a</sup>	Time point	No. analysed	Mean	$SD^b$
MUA + PT	6 weeks	55	4.9	NR
Home exercise		55	4.7	NR
MUA + PT	3 months	51	4.9	2.735
Home exercise		50	4.7	2.735
MUA + PT	6 months	38	2.0	NR
Home exercise		45	2.8	NR
MUA + PT	12 months	37	1.5	NR
Home exercise		42	2.2	NR
Outcome: Pain (pain intensity) ı	neasured using Likert	0–10 scale		
Intervention <sup>a</sup>	Time point	No. randomised	Mean	SD
MUA + PT vs home exercise	Baseline	125	NA	NA
Intervention <sup>a</sup>	Time point	No. analysed	Mean difference	95% CI
MUA + PT vs home exercise	6 weeks	110	0.2	-0.64 to 1.02
MUA + PT vs home exercise	3 months	101	0.2	-1.06 to 1.10
MUA + physical therapy vs home exercise	6 months	83	-0.8	-1.80 to 0.20
MUA + PT vs home exercise	12 months	79	-0.7	-1.80 to 0.40

NA, not applicable; NR, not reported; PT, physiotherapy.

b SD calculated from 95% Cl of mean difference.

Study: Kivimaki 2007 <sup>39</sup> Outcome: Function and disability measured with a modified version of the SDQ						
MUA + PT vs home exercise	Baseline	125	NA	NA		
Interventiona	Time point	No. analysed	Mean difference	95% CI		
MUA + PT vs home exercise	6 weeks	110	4	-3.8 to 11.8		
MUA + PT vs home exercise	3 months	101	0.3	-2.69 to 2.75		
MUA + PT vs home exercise	6 months	83	-1.7	-5.3 to 1.9		
MUA + PT vs home exercise	12 months	79	0	-3.2 to 3.2		

NA, not applicable; PT, physiotherapy.

a All interventions received concomitant home exercise.

a All interventions received concomitant home exercise.

Study: Kivimaki 2007 <sup>39</sup>				
Outcome: Range of movement	- passive abduction (	?)		
Intervention <sup>a</sup>	Time point	No. randomised	Mean	SD
MUA + PT vs home exercise	Baseline	125	NA	NA
Intervention <sup>a</sup>	Time point	No. analysed	Mean difference	95% CI
MUA+PT vs home exercise	6 weeks	110	10	-3.2 to 23.2
MUA + PT vs home exercise	3 months	101	9	-6 to 24
MUA + PT vs home exercise	6 months	83	9	-4 to 22
MUA + PT vs home exercise	12 months	79	7	–5 to 19
Outcome: Range of movement	– passive internal rota	tion (cm)		
Intervention <sup>a</sup>	Time point	No. randomised	Mean	SD
MUA + PT vs home exercise	Baseline	125	NA	NA
Intervention <sup>a</sup>	Time point	No. analysed	Mean difference	95% Cl
MUA + PT vs home exercise	6 weeks	110	4	-1 to 9
MUA + PT vs home exercise	3 months	101	-3	-7.4 to 2.4
MUA + PT vs home exercise	6 months	83	<b>-</b> 2	-7.4 to 3.4
MUA + PT vs home exercise	12 months	79	-1	-4.1 to 6.1
Outcome: Range of movement	– external rotation (°)			
Intervention <sup>a</sup>	Time point	No. randomised	Mean	SD
MUA + PT vs home exercise	Baseline	125	NA	NA
Intervention <sup>a</sup>	Time point	No. analysed	Mean difference	95% CI
MUA + PT vs home exercise	6 weeks	110	5	-2 to 12
MUA + PT vs home exercise	3 months	101	6	-3to 15
MUA + PT vs home exercise	6 months	83	6	-2 to 14
MUA + PT vs home exercise	12 months	79	4	-4.2 to 12.2

NA, not applicable; NR, not reported; PT, physiotherapy. a  $\,$  All interventions received concomitant home exercise.

Study: Kivimaki 2007<sup>39</sup>

Outcome: Quality of life

Study: Kivimaki 2007 <sup>39</sup>							
Outcome: Other – working ability							
Intervention <sup>a</sup>	Time point	No. randomised	Mean	SD			
MUA + PT vs home exercise	Baseline	125	NA	NA			
Intervention <sup>a</sup>	Time point	No. analysed	Mean difference	95% CI			
MUA + PT vs home exercise	6 weeks	110	0.4	-4.2 to 1.8			
MUA + PT vs home exercise	3 months	101	0	-0.8 to 0.8			
MUA + PT vs home exercise	6 months	83	0.5	-0.6 to 1.6			
MUA + PT vs home exercise	12 months	79	0.1	-0.8 to1.0			

Study: Kivimaki 200739

Outcome: Adverse events

There were no major complications during manipulation

Study: Quraishi 2007 <sup>38</sup>							
Outcome: Pain (pain overall), unspecified VAS							
Intervention <sup>a</sup>	Time point	No. randomised	Mean	Range	SD		
MUA + steroid injection	Baseline	17 (18 shoulders)	5.7	3.0-8.5	NR		
Arthrographic distension		19 (20 shoulders)	6.1	4.0–10	NR		
Intervention <sup>a</sup>	Time point	No. analysed	Mean	Range	SD		
MUA + steroid injection	2 months	15 (16 shoulders)	4.7	0-8.5	NR		
Arthrographic distension		18 (18 shoulders)	2.4	0–8.0	NR		
MUA + steroid injection	6 months	15 (16 shoulders)	2.7	0-9.0	0.64		
Arthrographic distension		18 (18 shoulders)	1.7	0–7.0	0.64		

NR, not reported.

NA, not applicable; PT, physiotherapy.
a All interventions received concomitant home exercise.

a All interventions received concomitant home exercise.

Study: Quraishi 2007 <sup>38</sup> Outcome: Function and disability measured using the Constant score						
MUA + steroid injection	Baseline	17 (18 shoulders)	36	26–66		
Arthrographic distension		19 (20 shoulders)	28.8	18–55		
Intervention <sup>a</sup>	Time point	No. analysed	Mean	$SD^b$	p-value <sup>c</sup>	
MUA + steroid injection	2 months	15 (16 shoulders)	58.5	NA		
Arthrographic distension		18 (18 shoulders)	57.4	NA		
MUA + steroid injection	6 months	15 (16 shoulders)	59.5	0.24	0.02	
Arthrographic distension		18 (18 shoulders)	65.9	0.24		

NA, not applicable.

- a All interventions received concomitant home exercise.
- b p-value at 6 months was used to compute SD.
- c *p*-value for between-group difference.

Study: Quraishi 200738					
Outcome: Range of movemen	t – external rotation (°	")			
Intervention <sup>a</sup>	Time point	No. randomised	Mean	SD	
MUA + steroid injection	Baseline	17 (18 shoulders)	NR	NR	
Arthrographic distension		19 (20 shoulders)	NR	NR	
Intervention <sup>a</sup>	Time point	No. analysed	Mean	SD	p-value <sup>b</sup>
MUA + steroid injection	6 months	15 (16 shoulders)	NR	NR	0.13
Arthrographic distension		18 (18 shoulders)	NR	NR	
Outcome: Range of movemen	t – internal rotation (°)	)			
Intervention <sup>a</sup>	Time point	No. randomised	Mean	SD	p-value
MUA + steroid injection	Baseline	17 (18 shoulders)	NR	NR	NR
Arthrographic distension		19 (20 shoulders)	NR	NR	
Intervention <sup>a</sup>	Time point	No. analysed	Mean	SD	p-value <sup>b</sup>
MUA + steroid injection	6 months	15 (16 shoulders)	NR	NR	0.48
Arthrographic distension		18 (18 shoulders)	NR	NR	
Outcome: Range of movemen	t – abduction (°)				
Intervention <sup>a</sup>	Time point	No. randomised	Mean	SD	p-value
MUA + steroid injection	Baseline	17 (18 shoulders)	NR	NR	NR
Arthrographic distension		19 (20 shoulders)	NR	NR	
Intervention <sup>a</sup>	Time point	No. analysed	Mean	SD	p-value <sup>b</sup>
MUA + steroid injection	6 months	15 (16 shoulders)	NR	NR	0.62
Arthrographic distension		18 (18 shoulders)	NR	NR	

NR, not reported.

- a All interventions received concomitant home exercise.
  b p-value for between-group difference.

Study: Quraishi 2007 <sup>38</sup>			
Outcome: Quality of life			
Not reported			
Study: Quraishi 2007 <sup>38</sup>			
Outcome: Other – satisfaction			
94% of patients were satisfied or very satisfied after arthrographic distension compared with 81% after MUA			
Study: Quraishi 2007 <sup>38</sup>			
Outcome: Adverse events			